OmniAb (OABI)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	27.80 mm	27.80 mm	27.80 mm	27.80 mm	27.80 mm	27.80 mm
Cash burn (monthly)	(no burn)	(no burn)	6.59 mm	6.65 mm	2.19 mm	3.74 mm
Cash used (since last report)	n/a	n/a	33.47 mm	33.80 mm	11.14 mm	19.02 mm
Cash remaining	n/a	n/a	-5.68 mm	-6.00 mm	16.66 mm	8.78 mm
Runway (months of cash)	n/a	n/a	-0.9	-0.9	7.6	2.3

Beta Read what these cash burn values mean

Financial data from OmniAb earnings reports.

Institutional ownership, Q4 2024

OABI institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	166	166	–
Opened positions	19	162	-88.3%
Closed positions	19	1	+1800.0%
Increased positions	51	1	+5000.0%
Reduced positions	46	0	NEW

13F shares	Current	Prev Q	Change
Total value	222.54 bn	326.96 bn	-31.9%
Total shares	123.27 mm	139.50 mm	-11.6%
Total puts	9.90 k	23.10 k	-57.1%
Total calls	32.40 k	38.50 k	-15.8%
Total put/call ratio	0.3	0.6	-49.1%

Largest owners	Shares	Value	Change
Avista Capital Managing Member V	27.21 mm	$102.03 mm	0.0%
Acquisition LP Avista II	27.16 mm	$96.43 mm	0.0%
JHG Janus Henderson	7.96 mm	$28.18 bn	+1.1%
BlackRock	7.18 mm	$25.41 bn	-0.6%
Integrated Core Strategies	5.37 mm	$0.00	0.0%
Vanguard	5.06 mm	$17.90 bn	-2.6%
MQBKY Macquarie Group Limited	4.30 mm	$15.23 bn	-0.5%
Dimensional Fund Advisors	3.03 mm	$10.71 bn	+4.9%
Chicago Capital	2.98 mm	$10.53 bn	-5.9%
Rubric Capital Management	2.85 mm	$10.09 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Avista Capital	0.00	-15.82 mm	EXIT
ADAR1 Capital Management	278.11 k	-1.06 mm	-79.2%
JPM JPMorgan Chase & Co.	1.00 mm	+854.93 k	+582.1%
Kent Lake PR	500.00 k	-625.00 k	-55.6%
Royce & Associates	707.08 k	+575.80 k	+438.6%
UBS UBS	306.39 k	+244.67 k	+396.4%
GS The Goldman Sachs Group, Inc.	548.54 k	+220.40 k	+67.2%
First Sabrepoint Capital Management	1.46 mm	-204.40 k	-12.3%
Chicago Capital	2.98 mm	-187.10 k	-5.9%
Citadel Advisors	437.97 k	+163.12 k	+59.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

OABI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Feb 25	Gustafson Kurt A	Common Stock	Sell	Dispose S	No	No	3.67	7,255	26.63 k	206,211
19 Feb 25	Foehr Matthew W	Common Stock	Sell	Dispose S	No	No	3.67	19,522	71.65 k	3,779,160
19 Feb 25	Berkman Charles S	Common Stock	Sell	Dispose S	No	No	3.67	7,255	26.63 k	356,876
18 Feb 25	Gustafson Kurt A	Stock Option Common Stock	Grant	Acquire A	No	No	3.66	337,500	1.24 mm	337,500
18 Feb 25	Gustafson Kurt A	RSU Common Stock	Grant	Acquire A	No	No	0	56,250	0.00	180,162
18 Feb 25	Foehr Matthew W	Common Stock	Sell	Dispose S	No	No	3.68	13,964	51.39 k	3,798,682
18 Feb 25	Foehr Matthew W	Stock Option Common Stock	Grant	Acquire A	No	No	3.66	1,050,000	3.84 mm	1,050,000
18 Feb 25	Foehr Matthew W	RSU Common Stock	Grant	Acquire A	No	No	0	175,000	0.00	347,388
18 Feb 25	Berkman Charles S	Common Stock	Sell	Dispose S	No	No	3.68	8,215	30.23 k	364,131
18 Feb 25	Berkman Charles S	Stock Option Common Stock	Grant	Acquire A	No	No	3.66	337,500	1.24 mm	337,500

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

OmniAb to Participate in Two Investor Conferences in March

3 Feb 25

OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45th Annual Health Care Conference, March 3-5 at the Boston Marriott

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

31 Jan 25

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of OmniAb, Inc. (NASDAQ:OABI) breached their fiduciary duties to

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

16 Dec 24

Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub™, a bioinformatics tools platform OmniAb, Inc. (NASDAQ:OABI) today announced that two presentations